The DOI matches its Crossref record; 271 of the 271 references it cites were found in a registry or an index.
Antifungal Resistance and New Strategies to Control Fungal Infections
Open accessAbstract
Despite improvement of antifungal therapies over the last 30 years, the phenomenon of antifungal resistance is still of major concern in clinical practice. In the last 10 years the molecular mechanisms underlying this phenomenon were extensively unraveled. In this paper, after a brief overview of currently available antifungals, molecular mechanisms of antifungal resistance will be detailed. It appears that major mechanisms of resistance are essential due to the deregulation of antifungal resistance effector genes. This deregulation is a consequence of point mutations occurring in transcriptional regulators of these effector genes. Resistance can also follow the emergence of point mutations directly in the genes coding antifungal targets. In addition we further describe new strategies currently undertaken to discover alternative therapy targets and antifungals. Identification of new antifungals is essentially achieved by the screening of natural or synthetic chemical compound collections. Discovery of new putative antifungal targets is performed through genome-wide approaches for a better understanding of the human pathogenic fungi biology.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ghannoum, M. A., & Rice, L. B. (1999) · Clinical Microbiology Reviews · doi:10.1128/cmr.12.4.501 · Cited by 1,785
Clinical, Cellular, and Molecular Factors That Contribute to Antifungal Drug Resistance
White, T. C., Marr, K. A., & Bowden, R. A. (1998) · Clinical Microbiology Reviews · doi:10.1128/cmr.11.2.382 · Cited by 1,353
Bennett, J. E., Dismukes, W. E., Duma, R. J., Medoff, G., Sande, M. A., Gallis, H., Leonard, J., Fields, B. T., Bradshaw, M., Haywood, H., et al. (1979) · New England Journal of Medicine · doi:10.1056/nejm197907193010303 · Cited by 863
Vermes, A. (2000) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/46.2.171 · Cited by 803
Aneuploidy and Isochromosome Formation in Drug-Resistant Candida albicans
Selmecki, A., Forche, A., & Berman, J. (2006) · Science · doi:10.1126/science.1128242 · Cited by 733
Noble, S. M., French, S., Kohn, L. A., Chen, V., & Johnson, A. D. (2010) · Nature Genetics · doi:10.1038/ng.605 · Cited by 678
Resistance to Antifungal Agents: Mechanisms and Clinical Impact
Kanafani, Z. A., & Perfect, J. R. (2008) · Clinical Infectious Diseases · doi:10.1086/524071 · Cited by 619
Efflux-Mediated Antifungal Drug Resistance
Cannon, R. D., Lamping, E., Holmes, A. R., Niimi, K., Baret, P. V., Keniya, M. V., Tanabe, K., Niimi, M., Goffeau, A., & Monk, B. C. (2009) · Clinical Microbiology Reviews · doi:10.1128/cmr.00051-08 · Cited by 608
Azole resistance in Aspergillus fumigatus: a side-effect of environmental fungicide use?
Verweij, P. E., Snelders, E., Kema, G. H., Mellado, E., & Melchers, W. J. (2009) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(09)70265-8 · Cited by 604
Noble, S. M., & Johnson, A. D. (2005) · Eukaryotic Cell · doi:10.1128/ec.4.2.298-309.2005 · Cited by 592
Espinel-Ingroff, A. (1998) · Journal of Clinical Microbiology · doi:10.1128/jcm.36.10.2950-2956.1998 · Cited by 576
Harriott, M. M., & Noverr, M. C. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00657-09 · Cited by 529
Calcineurin is required for virulence of Cryptococcus neoformans
Odom, A., Muir, S., Lim, E., Toffaletti, D. L., Perfect, J., & Heitman, J. (1997) · The EMBO Journal · doi:10.1093/emboj/16.10.2576 · Cited by 516
Roemer, T., Jiang, B., Davison, J., Ketela, T., Veillette, K., Breton, A., Tandia, F., Linteau, A., Sillaots, S., Marta, C., et al. (2003) · Molecular Microbiology · doi:10.1046/j.1365-2958.2003.03697.x · Cited by 512
Resistance to echinocandin-class antifungal drugs.
Perlin, D. S. (2007) · Drug Resistance Updates · doi:10.1016/j.drup.2007.04.002 · Cited by 512
Itraconazole resistance in Aspergillus fumigatus
Denning, D. W., Venkateswarlu, K., Oakley, K. L., Anderson, M. J., Manning, N. J., Stevens, D. A., Warnock, D. W., & Kelly, S. L. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.6.1364 · Cited by 508
Mellado, E., Garcia-Effron, G., Alcázar-Fuoli, L., Melchers, W. J. G., Verweij, P. E., Cuenca-Estrella, M., & Rodríguez-Tudela, J. L. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01092-06 · Cited by 490 · cited 1×
“In this species, it was demonstrated that the nature of the nucleotide mutation, and therefore, the nature of the amino acid substitution, influences the development of resistance to different azole agents [188–192].”
BackgroundHistory of the development of azole derivatives
Maertens, J. A. (2004) · Clinical Microbiology and Infection · doi:10.1111/j.1470-9465.2004.00841.x · Cited by 475
Amphotericin B: spectrum and resistance
Ellis, D. (2002) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/49.suppl_1.7 · Cited by 473
Perea, S., López-Ribot, J. L., Kirkpatrick, W. R., McAtee, R. K., Santillán, R. A., Martı́nez, M., Calabrese, D., Sanglard, D., & Patterson, T. F. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.10.2676-2684.2001 · Cited by 470
Sanglard, D., Ischer, F., Koymans, L., & Bille, J. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.2.241 · Cited by 465
Regulation of Cell-Surface Genes and Biofilm Formation by the C. albicans Transcription Factor Bcr1p
Nobile, C. J., & Mitchell, A. P. (2005) · Current Biology · doi:10.1016/j.cub.2005.05.047 · Cited by 464
A Phenotypic Profile of the Candida albicans Regulatory Network
Homann, O. R., Dea, J., Noble, S. M., & Johnson, A. D. (2009) · PLoS Genetics · doi:10.1371/journal.pgen.1000783 · Cited by 444 · cited 2×
“First of all, treating strains with already known antifungal drugs and analyzing for example, growth modification and later transcriptional rewiring, some authors try to better understand drugs mechanisms of action and/or to find synergistic effect between them [272, 274].”
BackgroundSystematic Genetic Analysis of Virulence in the Human Fungal Pathogen Cryptococcus neoformans
Liu, O. W., Chun, C. D., Chow, E. D., Chen, C., Madhani, H. D., & Noble, S. M. (2008) · Cell · doi:10.1016/j.cell.2008.07.046 · Cited by 443
Mayer, A., Rodríguez, A., Taglialatela-Scafati, O., & Fusetani, N. (2013) · Marine Drugs · doi:10.3390/md11072510 · Cited by 436
Park, S., Kelly, R., Kahn, J. N., Robles, J., Hsu, M.-J., Register, E., Li, W., Vyas, V., Fan, H., Abruzzo, G., et al. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.8.3264-3273.2005 · Cited by 434
Pharmacokinetics and Tissue Penetration of Fluconazole in Humans
Brammer, K. W., Farrow, P. R., & Faulkner, J. K. (1990) · Clinical Infectious Diseases · doi:10.1093/clinids/12.supplement_3.s318 · Cited by 429
Differential Expression and Function of Two Homologous Subunits of Yeast 1,3-β-D-Glucan Synthase
Mazur, P., Morin, N., Baginsky, W., el-Sherbeini, M., Clemas, J. A., Nielsen, J. B., & Foor, F. (1995) · Molecular and Cellular Biology · doi:10.1128/mcb.15.10.5671 · Cited by 424
Possible Environmental Origin of Resistance of Aspergillus fumigatus to Medical Triazoles
Snelders, E., Huis in 't Veld, R. A. G., Rijs, A. J. M. M., Kema, G. H. J., Melchers, W. J. G., & Verweij, P. E. (2009) · Applied and Environmental Microbiology · doi:10.1128/aem.00231-09 · Cited by 423
Ketoconazole Blocks Adrenal Steroid Synthesis
PONT, A., WILLIAMS, P. L., LOOSE, D. S., FELDMAN, D., REITZ, R. E., BOCHRA, C., & STEVENS, D. A. (1982) · Annals of Internal Medicine · doi:10.7326/0003-4819-97-3-370 · Cited by 422
Coste, A. T., Karababa, M., Ischer, F., Bille, J., & Sanglard, D. (2004) · Eukaryotic Cell · doi:10.1128/ec.3.6.1639-1652.2004 · Cited by 407
Self-citationNatural products – antifungal agents derived from plants
Arif, T., Bhosale, J. D., Kumar, N., Mandal, T. K., Bendre, R. S., Lavekar, G. S., & Dabur, R. (2009) · Journal of Asian Natural Products Research · doi:10.1080/10286020902942350 · Cited by 406
Sanglard, D., Ischer, F., Parkinson, T., Falconer, D., & Bille, J. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.8.2404-2412.2003 · Cited by 398 · cited 1×
“albicans [225] and ERG3 deletion in S.”
Overview of medically important antifungal azole derivatives
Fromtling, R. A. (1988) · Clinical Microbiology Reviews · doi:10.1128/cmr.1.2.187 · Cited by 398
Hepatic Injury Associated With Ketoconazole Therapy
Lewis, J. H., Zimmerman, H. J., Benson, G. D., & Ishak, K. G. (1984) · Gastroenterology · doi:10.1016/s0016-5085(84)80021-9 · Cited by 394
Pfaller, M. A., Boyken, L., Hollis, R. J., Kroeger, J., Messer, S. A., Tendolkar, S., & Diekema, D. J. (2008) · Journal of Clinical Microbiology · doi:10.1128/jcm.01901-07 · Cited by 387
Coste, A., Turner, V., Ischer, F., Morschhäuser, J., Forche, A., Selmecki, A., Berman, J., Bille, J., & Sanglard, D. (2006) · Genetics · doi:10.1534/genetics.105.054767 · Cited by 385
Self-citationMarichal, P., Koymans, L., Willemsens, S., Bellens, D., Verhasselt, P., Luyten, W., Borgers, M., Ramaekers, F. C. S., Odds, F. C., & Vanden Bossche, H. (1999) · Microbiology · doi:10.1099/00221287-145-10-2701 · Cited by 382
Epidemiology of invasive candidiasis
Arendrup, M. C. (2010) · Current Opinion in Critical Care · doi:10.1097/mcc.0b013e32833e84d2 · Cited by 376
Morschhäuser, J., Barker, K. S., Liu, T. T., Blaß-Warmuth, J., Homayouni, R., & Rogers, P. D. (2007) · PLoS Pathogens · doi:10.1371/journal.ppat.0030164 · Cited by 355
Kelly, S. L., Lamb, D. C., Kelly, D. E., Manning, N. J., Loeffler, J., Hebart, H., Schumacher, U., & Einsele, H. (1997) · FEBS Letters · doi:10.1016/s0014-5793(96)01360-9 · Cited by 351
Sanglard, D., Ischer, F., Marchetti, O., Entenza, J., & Bille, J. (2003) · Molecular Microbiology · doi:10.1046/j.1365-2958.2003.03495.x · Cited by 350 · cited 1×
“In particular, inhibitors of the calcineurin pathway were shown to be fully active in vivo in the potentiation of fluconazole, and they also led to a dramatic decrease in fungi virulence [256–260].”
BackgroundHeeres, J., Backx, L. J. J., Mostmans, J. H., & Van Cutsem, J. (1979) · Journal of Medicinal Chemistry · doi:10.1021/jm00194a023 · Cited by 343
Strategies in the Treatment of Systemic Fungal Infections
Medoff, G., & Kobayashi, G. S. (1980) · New England Journal of Medicine · doi:10.1056/nejm198001173020304 · Cited by 342
Franz, R., Kelly, S. L., Lamb, D. C., Kelly, D. E., Ruhnke, M., & Morschhäuser, J. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.12.3065 · Cited by 339
Sanglard, D., Ischer, F., Calabrese, D., Majcherczyk, P. A., & Bille, J. (1999) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.43.11.2753 · Cited by 337
Pfaller, M. A., Diekema, D. J., Andes, D., Arendrup, M. C., Brown, S. D., Lockhart, S. R., Motyl, M., & Perlin, D. S. (2011) · Drug Resistance Updates · doi:10.1016/j.drup.2011.01.004 · Cited by 334
REVIEW ARTICLE: Toenail onychomycosis: an important global disease burden
Thomas, J., Jacobson, G. A., Narkowicz, C. K., Peterson, G. M., Burnet, H., & Sharpe, C. (2010) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/j.1365-2710.2009.01107.x · Cited by 327
An isochromosome confers drug resistance in vivo by amplification of two genes, ERG11 and TAC1
Selmecki, A., Gerami‐Nejad, M., Paulson, C., Forche, A., & Berman, J. (2008) · Molecular Microbiology · doi:10.1111/j.1365-2958.2008.06176.x · Cited by 325 · cited 14×
“In contrast to azoles and ERG11, mutations in FKS1 did not alter the β-glucane synthase affinity for its target but decreased only the enzyme processivity [198].”
InfluentialPachl, J., Svoboda, P., Jacobs, F., Vandewoude, K., van der Hoven, B., Spronk, P., Masterson, G., Malbrain, M., Aoun, M., Garbino, J., et al. (2006) · Clinical Infectious Diseases · doi:10.1086/503428 · Cited by 307
Genotypic Evolution of Azole Resistance Mechanisms in Sequential Candida albicans Isolates
Coste, A., Selmecki, A., Forche, A., Diogo, D., Bougnoux, M.-E., d'Enfert, C., Berman, J., & Sanglard, D. (2007) · Eukaryotic Cell · doi:10.1128/ec.00151-07 · Cited by 305
Self-citationLemke, A., Kiderlen, A. F., & Kayser, O. (2005) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-005-1955-9 · Cited by 305
Echinocandins: a new class of antifungal
Denning, D. W. (2002) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkf045 · Cited by 300
Ferrari, S., Ischer, F., Calabrese, D., Posteraro, B., Sanguinetti, M., Fadda, G., Rohde, B., Bauser, C., Bader, O., & Sanglard, D. (2009) · PLoS Pathogens · doi:10.1371/journal.ppat.1000268 · Cited by 295
Self-citationFungal Biofilms and Drug Resistance
Jabra-Rizk, M. A., Falkler, W. A., & Meiller, T. F. (2004) · Emerging Infectious Diseases · doi:10.3201/eid1001.030119 · Cited by 292
An update on antifungal targets and mechanisms of resistance in Candidaalbicans
Akins, R. A. (2005) · Medical Mycology · doi:10.1080/13693780500138971 · Cited by 291
Antifungal Resistance in Pathogenic Fungi
Perea, S., & Patterson, T. F. (2002) · Clinical Infectious Diseases · doi:10.1086/344058 · Cited by 289
Antifungal agents: mode of action in yeast cells.
Carrillo‐Muñoz, A. J., Giusiano, G., Ezkurra, P. A., & Quindós, G. (2006) · PubMed · Cited by 286
Vermitsky, J.-P., & Edlind, T. D. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.10.3773-3781.2004 · Cited by 285 · cited 1×
“Three studies have identified separate gain-of-function mutations in CgPDR1 alleles of azole-resistant strains which are responsible for constitutive high expression of CgCDR1, CgCDR2, SNQ2, and CgPDR1 itself (Figure 9) [120, 145, 146].”
BackgroundDiaz-Guerra, T. M., Mellado, E., Cuenca-Estrella, M., & Rodriguez-Tudela, J. L. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.3.1120-1124.2003 · Cited by 281
Systemic Antifungal Agents: Drug Interactions of Clinical Significance
Albengres Herv??, E., Lou??, L., & Tillement, J.-P. (1998) · Drug Safety · doi:10.2165/00002018-199818020-00001 · Cited by 280
Morio, F., Loge, C., Besse, B., Hennequin, C., & Le Pape, P. (2010) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2009.11.006 · Cited by 279
Dunkel, N., Blaß, J., Rogers, P. D., & Morschhäuser, J. (2008) · Molecular Microbiology · doi:10.1111/j.1365-2958.2008.06309.x · Cited by 278
Pfaller, M. A., Messer, S. A., Moet, G. J., Jones, R. N., & Castanheira, M. (2011) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2011.02.016 · Cited by 274
Mayer, A. M. S., Rodríguez, A. D., Berlinck, R. G. S., & Fusetani, N. (2011) · Comparative Biochemistry and Physiology Part C: Toxicology & Pharmacology · doi:10.1016/j.cbpc.2010.08.008 · Cited by 270
Comparative amino acid sequence analysis of the C6 zinc cluster family of transcriptional regulators
Schjerling, P. (1996) · Nucleic Acids Research · doi:10.1093/nar/24.23.4599 · Cited by 267
Calcineurin Controls Growth, Morphology, and Pathogenicity in Aspergillus fumigatus
Steinbach, W. J., Cramer, R. A., Perfect, B. Z., Asfaw, Y. G., Sauer, T. C., Najvar, L. K., Kirkpatrick, W. R., Patterson, T. F., Benjamin, D. K., Heitman, J., et al. (2006) · Eukaryotic Cell · doi:10.1128/ec.00139-06 · Cited by 264
Nascimento, A. M., Goldman, G. H., Park, S., Marras, S. A. E., Delmas, G., Oza, U., Lolans, K., Dudley, M. N., Mann, P. A., & Perlin, D. S. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.5.1719-1726.2003 · Cited by 258
Garcia-Effron, G., Park, S., & Perlin, D. S. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01162-08 · Cited by 256
Molecular mechanisms of drug resistance in fungi
Vanden Bossche, H., Marichal, P., & Odds, F. C. (1994) · Trends in Microbiology · doi:10.1016/0966-842x(94)90618-1 · Cited by 254
Genome-Wide Fitness Test and Mechanism-of-Action Studies of Inhibitory Compounds in Candida albicans
Xu, D., Jiang, B., Ketela, T., Lemieux, S., Veillette, K., Martel, N., Davison, J., Sillaots, S., Trosok, S., Bachewich, C., et al. (2007) · PLoS Pathogens · doi:10.1371/journal.ppat.0030092 · Cited by 254
Potent Synergism of the Combination of Fluconazole and Cyclosporine in Candida albicans
Marchetti, O., Moreillon, P., Glauser, M. P., Bille, J., & Sanglard, D. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.9.2373-2381.2000 · Cited by 252
Polyene Macrolide Antibiotics and their Applications in Human Therapy
Zotchev, S. (2003) · Current Medicinal Chemistry · doi:10.2174/0929867033368448 · Cited by 251
Mode of action of 5-fluorocytosine and mechanisms of resistance
Polak, A., & Scholer, H. J. (2009) · Chemotherapy · doi:10.1159/000221854 · Cited by 250 · cited 7×
“Numerous enzymes of the pyrimidine salvage pathway are involved in 5FC mode of action and thus numerous molecular mechanisms could lead to resistance to this drug [16, 204].”
BackgroundInfluentialCaffrey, P., Lynch, S., Flood, E., Finnan, S., & Oliynyk, M. (2001) · Chemistry & Biology · doi:10.1016/s1074-5521(01)00046-1 · Cited by 250
Sanglard, D., Ischer, F., & Bille, J. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.4.1174-1183.2001 · Cited by 247
Toxicity of amphotericin B plus flucytosine in 194 patients with cryptococcal meningitis
Stamm, A. M., Diasio, R. B., Dismukes, W. E., Shadomy, S., Cloud, G. A., Bowles, C. A., Karam, G. H., & Espinel-Ingroff, A. (1987) · The American Journal of Medicine · doi:10.1016/0002-9343(87)90691-7 · Cited by 244
Alarco, A.-M., & Raymond, M. (1999) · Journal of Bacteriology · doi:10.1128/jb.181.3.700-708.1999 · Cited by 243
Compounds active against cell walls of medically important fungi
Hector, R. F. (1993) · Clinical Microbiology Reviews · doi:10.1128/cmr.6.1.1 · Cited by 242
(2003) · PubMed · Cited by 240
Pfaller, M. A., Moet, G. J., Messer, S. A., Jones, R. N., & Castanheira, M. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01079-10 · Cited by 238
MacPherson, S., Akache, B., Weber, S., De Deken, X., Raymond, M., & Turcotte, B. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.5.1745-1752.2005 · Cited by 238
Essential Gene Identification and Drug Target Prioritization in Aspergillus fumigatus
Hu, W., Sillaots, S., Lemieux, S., Davison, J., Kauffman, S., Breton, A., Linteau, A., Xin, C., Bowman, J., Becker, J., et al. (2007) · PLoS Pathogens · doi:10.1371/journal.ppat.0030024 · Cited by 237
Tsai, H.-F., Krol, A. A., Sarti, K. E., & Bennett, J. E. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.50.4.1384-1392.2006 · Cited by 237
Dunkel, N., Liu, T. T., Barker, K. S., Homayouni, R., Morschhäuser, J., & Rogers, P. D. (2008) · Eukaryotic Cell · doi:10.1128/ec.00103-08 · Cited by 236
Mortensen, K. L., Mellado, E., Lass-Flörl, C., Rodriguez-Tudela, J. L., Johansen, H. K., & Arendrup, M. C. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00692-10 · Cited by 233
Vermitsky, J., Earhart, K. D., Smith, W. L., Homayouni, R., Edlind, T. D., & Rogers, P. D. (2006) · Molecular Microbiology · doi:10.1111/j.1365-2958.2006.05235.x · Cited by 233
Francis, P., & Walsh, T. J. (1992) · Clinical Infectious Diseases · doi:10.1093/clind/15.6.1003 · Cited by 232
Amphotericin B-resistant yeast infection in severely immunocompromised patients
Powderly, W. G., Kobayashi, G. S., Herzig, G. P., & Medoff, G. (1988) · The American Journal of Medicine · doi:10.1016/0002-9343(88)90059-9 · Cited by 232
Seidler, M. J., Salvenmoser, S., & Müller, F.-M. C. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00234-08 · Cited by 229
Pfaller, M. A., Moet, G. J., Messer, S. A., Jones, R. N., & Castanheira, M. (2011) · Journal of Clinical Microbiology · doi:10.1128/jcm.01398-10 · Cited by 228
Di Bonaventura, G., Pompilio, A., Picciani, C., Iezzi, M., D'Antonio, D., & Piccolomini, R. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00556-06 · Cited by 226
Balashov, S. V., Park, S., & Perlin, D. S. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01653-05 · Cited by 225
MUKHERJEE, P., & CHANDRA, J. (2004) · Drug Resistance Updates · doi:10.1016/j.drup.2004.09.002 · Cited by 222
Nolte, F. S., Parkinson, T., Falconer, D. J., Dix, S., Williams, J., Gilmore, C., Geller, R., & Wingard, J. R. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.1.196 · Cited by 219
Mechanism of Increased Fluconazole Resistance in Candida glabrata during Prophylaxis
Bennett, J. E., Izumikawa, K., & Marr, K. A. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.5.1773-1777.2004 · Cited by 217 · cited 1×
“glabrata, CgCDR1 and CgCDR2 (formerly denoted PDH1) as well as SNQ2 (another ABC transporter coregulated with CgCDR1 and CgCDR2) are upregulated in azole-resistant clinical isolates and participate in azole resistance [114–118].”
BackgroundUpregulation of ERG Genes in Candida Species by Azoles and Other Sterol Biosynthesis Inhibitors
Henry, K. W., Nickels, J. T., & Edlind, T. D. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.10.2693-2700.2000 · Cited by 216 · cited 1×
“albicans, glabrata, tropicalis, and krusei [208].”
Role of Candida albicans Transcription Factor Upc2p in Drug Resistance and Sterol Metabolism
Silver, P. M., Oliver, B. G., & White, T. C. (2004) · Eukaryotic Cell · doi:10.1128/ec.3.6.1391-1397.2004 · Cited by 216 · cited 4×
“Moreover, the upc2 Δ/Δ mutant shows increased susceptibility to most drugs and a decrease in sterol uptake as compared to the wild-type strain [214, 215].”
BackgroundInfluentialTranscriptional control of the yeast PDR5 gene by the PDR3 gene product.
Katzmann, D. J., Burnett, P. E., Golin, J., Mahé, Y., & Moye-Rowley, W. S. (1994) · Molecular and Cellular Biology · doi:10.1128/mcb.14.7.4653 · Cited by 216
Lipopeptide inhibitors of fungal glucan synthase
Kurtz, M. B., & Douglas, C. M. (1997) · Medical Mycology · doi:10.1080/02681219780000961 · Cited by 216
Mechanism of Action of Antifungal Drugs, with Special Reference to the Imidazole Derivatives
Borgers, M. (1980) · Clinical Infectious Diseases · doi:10.1093/clinids/2.4.520 · Cited by 215
Chang, Y. C., Bien, C. M., Lee, H., Espenshade, P. J., & Kwon‐Chung, K. J. (2007) · Molecular Microbiology · doi:10.1111/j.1365-2958.2007.05676.x · Cited by 212
Molecular biological characterization of an azole-resistant Candida glabrata isolate
Marichal, P., Vanden Bossche, H., Odds, F. C., Nobels, G., Warnock, D. W., Timmerman, V, Van Broeckhoven, C., Fay, S., & Mose-Larsen, P. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.10.2229 · Cited by 210
Disposition of ketoconazole, an oral antifungal, in humans
Brass, C., Galgiani, J. N., Blaschke, T. F., Defelice, R., O'Reilly, R. A., & Stevens, D. A. (1982) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.21.1.151 · Cited by 210
Mellado, E., Garcia-Effron, G., Alcazar-Fuoli, L., Cuenca-Estrella, M., & Rodriguez-Tudela, J. L. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.7.2747-2750.2004 · Cited by 210
Barone, J. A., Moskovitz, B. L., Guarnieri, J., Hassell, A. E., Colaizzi, J. L., Bierman, R. H., & Jessen, L. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.7.1862 · Cited by 208
Cappelletty, D., & Eiselstein‐McKitrick, K. (2007) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.27.3.369 · Cited by 205
Fling, M. E., Kopf, J., Tamarkin, A., Gorman, J. A., Smith, H. A., & Koltin, Y. (1991) · Molecular and General Genetics MGG · doi:10.1007/bf00259685 · Cited by 204
Slaven, J. W., Anderson, M. J., Sanglard, D., Dixon, G. K., Bille, J., Roberts, I. S., & Denning, D. W. (2002) · Fungal Genetics and Biology · doi:10.1016/s1087-1845(02)00016-6 · Cited by 202 · cited 1×
“fumigatus, atrF, and AfuMDR4 are upregulated in itraconazole-resistant strains [128–130].”
BackgroundVoriconazole: A New Triazole Antifungal
Sabo, J., & Abdel‐Rahman, S. M. (2000) · Annals of Pharmacotherapy · doi:10.1345/aph.19237 · Cited by 199
Chen, J., Li, H., Li, R., Bu, D., & Wan, Z. (2005) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkh507 · Cited by 198
Moran, G. P., Sanglard, D., Donnelly, S. M., Shanley, D. B., Sullivan, D. J., & Coleman, D. C. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.7.1819 · Cited by 197
Stevens, D. A., Ichinomiya, M., Koshi, Y., & Horiuchi, H. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00563-06 · Cited by 193 · cited 1×
“This response is the direct consequence of the β(1-3)-glucans synthesis inhibition and the subsequent cell wall composition modifications, upon echinocandin administration [218, 219].”
BackgroundPukkila-Worley, R., Peleg, A. Y., Tampakakis, E., & Mylonakis, E. (2009) · Eukaryotic Cell · doi:10.1128/ec.00163-09 · Cited by 192
The fungal cell wall as a drug target
Georgopapadakou, N. (1995) · Trends in Microbiology · doi:10.1016/s0966-842x(00)88890-3 · Cited by 191
A systematic review of the antifungal effectiveness and tolerability of amphotericin B formulations
Barrett, J. P., Vardulaki, K. A., Conlon, C., Cooke, J., Daza-Ramirez, P., Evans, E. G. V., Hawkey, P. M., Herbrecht, R., Marks, D. I., Moraleda, J. M., et al. (2003) · Clinical Therapeutics · doi:10.1016/s0149-2918(03)80125-x · Cited by 190
Mann, P. A., Parmegiani, R. M., Wei, S.-Q., Mendrick, C. A., Li, X., Loebenberg, D., DiDomenico, B., Hare, R. S., Walker, S. S., & McNicholas, P. M. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.2.577-581.2003 · Cited by 189
Katiyar, S., Pfaller, M., & Edlind, T. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00349-06 · Cited by 189
Calcineurin Is Essential for Candida albicans Survival in Serum and Virulence
Blankenship, J. R., Wormley, F. L., Boyce, M. K., Schell, W. A., Filler, S. G., Perfect, J. R., & Heitman, J. (2003) · Eukaryotic Cell · doi:10.1128/ec.2.3.422-430.2003 · Cited by 186
Disruption of Ergosterol Biosynthesis Confers Resistance to Amphotericin B in Candida lusitaniae
Young, L. Y., Hull, C. M., & Heitman, J. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.9.2717-2724.2003 · Cited by 186
Diethylcarbamazine-related antimicrobial activity in Mycobacterium tuberculosis-infected blood
Kitchen, L. (1998) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/42.2.241 · Cited by 183
Micheli, M. D., Bille, J., Schueller, C., & Sanglard, D. (2002) · Molecular Microbiology · doi:10.1046/j.1365-2958.2002.02814.x · Cited by 182
Maligie, M. A., & Selitrennikoff, C. P. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.7.2851-2856.2005 · Cited by 178
Clinical Pharmacokinetics of Systemic Antifungal Drugs
Daneshmend, T. K., & Warnock, D. W. (1983) · Clinical Pharmacokinetics · doi:10.2165/00003088-198308010-00002 · Cited by 177
Mecanismos de resistencia a los antifúngicos: levaduras y hongos filamentosos
Espinel‐Ingroff, A. (2008) · Revista Iberoamericana de Micología · doi:10.1016/s1130-1406(08)70027-5 · Cited by 177
Chamilos, G., Lewis, R. E., Albert, N., & Kontoyiannis, D. P. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00095-07 · Cited by 171
Mechanisms of Azole Resistance in a Clinical Isolate of Candida tropicalis
Vandeputte, P., Larcher, G., Bergès, T., Rénier, G., Chabasse, D., & Bouchara, J. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.11.4608-4615.2005 · Cited by 170
Self-citationCruz, M. C., Cavallo, L. M., Görlach, J. M., Cox, G., Perfect, J. R., Cardenas, M. E., & Heitman, J. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.6.4101 · Cited by 169
Arndt, C. A. S., Walsh, T. J., McCully, C. L., Balis, F. M., Pizzo, P. A., & Poplack, D. G. (1988) · Journal of Infectious Diseases · doi:10.1093/infdis/157.1.178 · Cited by 169
Identification and Characterization of Four Azole-Resistant erg3 Mutants of Candida albicans
Martel, C. M., Parker, J. E., Bader, O., Weig, M., Gross, U., Warrilow, A. G. S., Rolley, N., Kelly, D. E., & Kelly, S. L. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00348-10 · Cited by 168
Marr, K. A., Lyons, C. N., Rustad, T., Bowden, R. A., & White, T. C. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.10.2584 · Cited by 166 · cited 1×
“This increase in resistance along antifungal treatment is due to the sequential acquisition of different mechanisms [104–106].”
BackgroundTassel, D. (1968) · JAMA · doi:10.1001/jama.206.4.830 · Cited by 164
Niewerth, M., Kunze, D., Seibold, M., Schaller, M., Körting, H. C., & Hube, B. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.6.1805-1817.2003 · Cited by 162
Molecular Mechanisms of Primary Resistance to Flucytosine in Candida albicans
Hope, W. W., Tabernero, L., Denning, D. W., & Anderson, M. J. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.11.4377-4386.2004 · Cited by 160
Cruz, M. C., Goldstein, A. L., Blankenship, J., Del Poeta, M., Perfect, J. R., McCusker, J. H., Bennani, Y. L., Cardenas, M. E., & Heitman, J. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.11.3162-3170.2001 · Cited by 159
Holmes, A. R., Lin, Y.-H., Niimi, K., Lamping, E., Keniya, M., Niimi, M., Tanabe, K., Monk, B. C., & Cannon, R. D. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00463-08 · Cited by 159
Control of the C. albicans Cell Wall Damage Response by Transcriptional Regulator Cas5
Bruno, V. M., Kalachikov, S., Subaran, R., Nobile, C. J., Kyratsous, C., & Mitchell, A. P. (2006) · PLoS Pathogens · doi:10.1371/journal.ppat.0020021 · Cited by 157
The Growing Problem of Mycoses in Patients Infected with the Human Immunodeficiency Virus
Diamond, R. D. (1991) · Clinical Infectious Diseases · doi:10.1093/clinids/13.3.480 · Cited by 155
The influence of gastric acidity on the bio-availability of ketoconazole
van der Meer, J. W. M., Keuning, J. J., Scheijgrond, H. W., Heykants, J. J. P., Cutsem, J. V., & Brugmans, J. P. (1980) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/6.4.552 · Cited by 154
Bone Marrow Toxicity Associated with 5-Fluorocytosine Therapy
Kauffman, C. A., & Frame, P. T. (1977) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.11.2.244 · Cited by 151
Analysis of the oxidative stress regulation of the Candida albicans transcription factor, Cap1p
Zhang, X., De Micheli, M., Coleman, S. T., Sanglard, D., & Moye‐Rowley, W. S. (2000) · Molecular Microbiology · doi:10.1046/j.1365-2958.2000.01877.x · Cited by 146 · cited 1×
“MDR1 expression was shown to be regulated by at least four trans-acting factors: Cap1p [175–177], Mrr1p [178, 179], Upc2p [180, 181], and Mcm1p [182].”
BackgroundThe use of chitosan to damage Cryptococcus neoformans biofilms
Martinez, L. R., Mihu, M. R., Han, G., Frasés, S., Cordero, R. J. B., Casadevall, A., Friedman, A., Friedman, J. M., & Nosanchuk, J. D. (2009) · Biomaterials · doi:10.1016/j.biomaterials.2009.09.087 · Cited by 146
Candida albicans gene encoding resistance to benomyl and methotrexate is a multidrug resistance gene
Ben-Yaacov, R., Knoller, S., Caldwell, G. A., Becker, J. M., & Koltin, Y. (1994) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.38.4.648 · Cited by 144
Heilmann, C. J., Schneider, S., Barker, K. S., Rogers, P. D., & Morschhäuser, J. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01102-09 · Cited by 142
Delahodde, A., Delaveau, T., & Jacq, C. (1995) · Molecular and Cellular Biology · doi:10.1128/mcb.15.8.4043 · Cited by 142
A Ser678Pro Substitution in Fks1p Confers Resistance to Echinocandin Drugs in Aspergillus fumigatus
Rocha, E. M. F., Garcia-Effron, G., Park, S., & Perlin, D. S. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00917-07 · Cited by 141
Torelli, R., Posteraro, B., Ferrari, S., La Sorda, M., Fadda, G., Sanglard, D., & Sanguinetti, M. (2008) · Molecular Microbiology · doi:10.1111/j.1365-2958.2008.06143.x · Cited by 141 · cited 1×
“glabrata, CgCDR1 and CgCDR2 (formerly denoted PDH1) as well as SNQ2 (another ABC transporter coregulated with CgCDR1 and CgCDR2) are upregulated in azole-resistant clinical isolates and participate in azole resistance [114–118].”
BackgroundSelf-citationMechanisms of action of 5-fluorocytosine
Waldorf, A. R., & Polak, A. (1983) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.23.1.79 · Cited by 141
Caspofungin: An echinocandin antifungal agent
Stone, E. A., Fung, H. B., & Kirschenbaum, H. L. (2002) · Clinical Therapeutics · doi:10.1016/s0149-2918(02)85039-1 · Cited by 139
War1p, a Novel Transcription Factor Controlling Weak Acid Stress Response in Yeast
Kren, A., Mamnun, Y. M., BAUER, B. E., Schüller, C., Wolfger, H., Hatzixanthis, K., Mollapour, M., Gregori, C., Piper, P. W., & Kuchler, K. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.5.1775-1785.2003 · Cited by 139
Cruz, M. C., Poeta, M. D., Wang, P., Wenger, R. M., Zenke, G., Quesniaux, V. F. J., Movva, N. R., Perfect, J. R., Cardenas, M. E., & Heitman, J. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.1.143-149.2000 · Cited by 138
Genome-Wide Expression and Location Analyses of the Candida albicans Tac1p Regulon
Liu, T. T., Znaidi, S., Barker, K. S., Xu, L., Homayouni, R., Saidane, S., Morschhäuser, J., Nantel, A., Raymond, M., & Rogers, P. D. (2007) · Eukaryotic Cell · doi:10.1128/ec.00327-07 · Cited by 137
Yeast putative transcription factors involved in salt tolerance
Mendizabal, I., Rios, G., Mulet, J. M., Serrano, R., & de Larrinoa, I. F. (1998) · FEBS Letters · doi:10.1016/s0014-5793(98)00249-x · Cited by 136 · cited 1×
“Since the DRE motifs present in the promoter of CDR genes contains two CGG triplets that are potentially recognized by Zn2-Cys6 transcription factors (TF) [154–157], it was likely that one of the 78 ORFs encoding proteins with Zn2-Cys6 signatures could be involved in the regulation of CDR1 and CDR2.”
BackgroundPfaller, M. A., Messer, S. A., Gee, S. F., Joly, S., Pujol, C., Sullivan, D. J., Coleman, D. C., & Soll, D. R. (1999) · Journal of Clinical Microbiology · doi:10.1128/jcm.37.3.870-872.1999 · Cited by 136
Schubert, S., Barker, K. S., Znaidi, S., Schneider, S., Dierolf, F., Dunkel, N., Aïd, M., Boucher, G., Rogers, P. D., Raymond, M., et al. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01343-10 · Cited by 135 · cited 1×
“Interestingly, hyperactive Mrr1 proteins were also shown to be able to confer Mdr1pindependent drug resistance probably through the regulation of oxydoreductases implicated in the detoxification of yeast cells after fluconazole exposure [183].”
BackgroundAntibiotic resistance surveillance: action for international studies
Morris, A. K., & Masterton, R. G. (2002) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/49.1.7 · Cited by 135
Feldmesser, M., Kress, Y., Mednick, A. J., & Casadevall, A. (2000) · The Journal of Infectious Diseases · doi:10.1086/317614 · Cited by 134
Crystal Structure of Yeast Cytosine Deaminase
Ko, T., Lin, J., Hu, C.-Y., Hsu, Y.-H., Wang, A. H. ‐., & Liaw, S. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m300874200 · Cited by 133
Pfaller, M. A., Castanheira, M., Messer, S. A., Moet, G. J., & Jones, R. N. (2010) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2010.08.013 · Cited by 131
Molecular Properties of Amphotericin B Membrane Channel: A Molecular Dynamics Simulation
Bagiński, M., Resat, H., & McCammon, J. A. (1997) · Molecular Pharmacology · doi:10.1124/mol.52.4.560 · Cited by 131
Antifungal Agents. Part II. The Azoles
Terrell, C. L. (1999) · Mayo Clinic Proceedings · doi:10.4065/74.1.78 · Cited by 130
In vitro studies with R 51,211 (itraconazole)
Espinel-Ingroff, A. V., Shadomy, S., & Gebhart, R. J. (1984) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.26.1.5 · Cited by 129
Diasio, R. B., Lakings, D. E., & Bennett, J. E. (1978) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.14.6.903 · Cited by 128
Conversion of 5-fluorocytosine to 5-fluorouracil by human intestinal microflora
Harris, B., Manning, B. W., Federle, T. W., & Diasio, R. B. (1986) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.29.1.44 · Cited by 128
Tsao, S., Rahkhoodaee, F., & Raymond, M. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00926-08 · Cited by 126
Semighini, C. P., Marins, M., Goldman, M. H. S., & Goldman, G. H. (2002) · Applied and Environmental Microbiology · doi:10.1128/aem.68.3.1351-1357.2002 · Cited by 126
Mamnun, Y. M., Pandjaitan, R., Mahé, Y., Delahodde, A., & Kuchler, K. (2002) · Molecular Microbiology · doi:10.1046/j.1365-2958.2002.03262.x · Cited by 125
New Drugs and Novel Targets for Treatment of Invasive Fungal Infections in Patients with Cancer
Chiou, C. C., Groll, A. H., & Walsh, T. J. (2000) · The Oncologist · doi:10.1634/theoncologist.5-2-120 · Cited by 124
Franzot, S. P., & Casadevall, A. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.2.331 · Cited by 122
Sharma, M., Manoharlal, R., Shukla, S., Puri, N., Prasad, T., Ambudkar, S. V., & Prasad, R. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01497-08 · Cited by 122
Jensen-Pergakes, K. L., Kennedy, M. A., Lees, N. D., Barbuch, R., Koegel, C., & Bard, M. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.5.1160 · Cited by 121
Znaidi, S., Weber, S., Zin Al-Abdin, O., Bomme, P., Saidane, S., Drouin, S., Lemieux, S., De Deken, X., Robert, F., & Raymond, M. (2008) · Eukaryotic Cell · doi:10.1128/ec.00070-08 · Cited by 119
Characterization ofAspergillus fumigatusmutants with reduced susceptibility to caspofungin
Gardiner, R. E., Souteropoulos, P., Park, S., & Perlin, D. S. (2005) · Medical Mycology · doi:10.1080/13693780400029023 · Cited by 119
Acquired Echinocandin Resistance in a Candida krusei Isolate Due to Modification of Glucan Synthase
Kahn, J. N., Garcia-Effron, G., Hsu, M.-J., Park, S., Marr, K. A., & Perlin, D. S. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00067-07 · Cited by 118
Heel, R. C., Brogden, R. N., Pakes, G. E., Speight, T. M., & Avery, G. S. (1980) · Drugs · doi:10.2165/00003495-198019010-00002 · Cited by 117
Antifungal Agents. Part I. Amphotericin B Preparations and Flucytosine
Patel, R. (1998) · Mayo Clinic Proceedings · doi:10.4065/73.12.1205 · Cited by 117
Vandeputte, P., Tronchin, G., Larcher, G., Ernoult, E., Bergès, T., Chabasse, D., & Bouchara, J.-P. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00423-08 · Cited by 117
Self-citationCorrelation between In Vitro and In Vivo Activity of Antifungal Agents against Candida Species
Anaissie, E. J., Karyotakis, N. C., Hachem, R., Dignani, M. C., & Rex, J. H. (1994) · The Journal of Infectious Diseases · doi:10.1093/infdis/170.2.384 · Cited by 117
Identification of the Candida albicans Cap1p Regulon
Znaidi, S., Barker, K. S., Weber, S., Alarco, A.-M., Liu, T. T., Boucher, G., Rogers, P. D., & Raymond, M. (2009) · Eukaryotic Cell · doi:10.1128/ec.00002-09 · Cited by 115
Pierce, G. E. (2005) · Journal of Industrial Microbiology & Biotechnology · doi:10.1007/s10295-005-0225-2 · Cited by 115
Natural products as antifungal agents against clinically relevant pathogens
Di Santo, R. (2010) · Natural Product Reports · doi:10.1039/b914961a · Cited by 115
BOSSCHE, H. V., Marichal, P., Gorrens, J., Bellens, D., Moereels, H., & Janssen, P. A. J. (1990) · Biochemical Society Transactions · doi:10.1042/bst0180056 · Cited by 114
Marchetti, O., Entenza, J. M., Sanglard, D., Bille, J., Glauser, M. P., & Moreillon, P. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.11.2932-2938.2000 · Cited by 113
Contribution of CgPDR1-Regulated Genes in Enhanced Virulence of Azole-Resistant Candida glabrata
Ferrari, S., Sanguinetti, M., Torelli, R., Posteraro, B., & Sanglard, D. (2011) · PLoS ONE · doi:10.1371/journal.pone.0017589 · Cited by 110
Self-citationVandeputte, P., Tronchin, G., Bergès, T., Hennequin, C., Chabasse, D., & Bouchara, J.-P. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01510-06 · Cited by 109 · cited 1×
“glabrata [230, 231].”
Self-citationJohnson, M. E., Katiyar, S. K., & Edlind, T. D. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01811-10 · Cited by 107
Nguyên, D.-T., Alarco, A., & Raymond, M. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m008377200 · Cited by 107
MDR1 -Mediated Drug Resistance in Candida dubliniensis
Wirsching, S., Moran, G. P., Sullivan, D. J., Coleman, D. C., & Morschhäuser, J. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.12.3416-3421.2001 · Cited by 106
Multiple resistance mechanisms to azole antifungals in yeast clinical isolates
Sanglard, D., Ischer, F., Calabrese, D. R., de Micheli, M., & Billé, J. (1998) · Drug Resistance Updates · doi:10.1016/s1368-7646(98)80006-x · Cited by 106
Polak, A., & Grenson, M. (1973) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1973.tb02608.x · Cited by 105
Identification and expression of multidrug resistancerelated ABC transporter genes in Candida krusei
Katiyar, S. K., & Edlind, T. D. (2001) · Medical Mycology · doi:10.1080/mmy.39.1.109.116 · Cited by 104
Studies of the paradoxical effect of caspofungin at high drug concentrations
Stevens, D. A., White, T. C., Perlin, D. S., & Selitrennikoff, C. P. (2005) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2004.10.006 · Cited by 103
Antifúngicos: mecanismo de acción en células de levaduras
Quindós, G., Giusiano, G., Ezkurra, P. A., & Muñoz, A. J. C. (2006) · Revista española de quimioterapia. Suplemento · Cited by 102
Oh, J., Fung, E., Schlecht, U., Davis, R. W., Giaever, G. N., St.Onge, R. P., Deutschbauer, A. M., & Nislow, C. (2010) · PLoS Pathogens · doi:10.1371/journal.ppat.1001140 · Cited by 102
Talibi, D., & Raymond, M. (1999) · Journal of Bacteriology · doi:10.1128/jb.181.1.231-240.1999 · Cited by 101
Homozygosity at the Candida albicans MTL locus associated with azole resistance
Rustad, T. R., Stevens, D. A., Pfaller, M. A., & White, T. C. (2002) · Microbiology · doi:10.1099/00221287-148-4-1061 · Cited by 101
In Vitro Studies of 5-Fluorocytosine Resistance in Candida albicans and Torulopsis glabrata
Normark, S. J., & Schönebeck, J. (1972) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.2.3.114 · Cited by 100
Crom, S. L., Devaux, F., Marc, P., Zhang, X., Moye-Rowley, S., & Jacq, C. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.8.2642-2649.2002 · Cited by 100
Lamping, E., Ranchod, A., Nakamura, K., Tyndall, J. D. A., Niimi, K., Holmes, A. R., Niimi, M., & Cannon, R. D. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01095-08 · Cited by 100
Stiller, R. L., Bennett, J. E., Scholer, H. J., Wall, M., Polak, A., & Stevens, D. A. (1983) · The Journal of Infectious Diseases · doi:10.1093/infdis/147.6.1070 · Cited by 100
Cited by
Campoy, S., & Adrio, J. L. (2017) · Biochemical Pharmacology · doi:10.1016/j.bcp.2016.11.019 · Cited by 511
Candidiasis and Mechanisms of Antifungal Resistance
Bhattacharya, S., Sae-Tia, S., & Fries, B. C. (2020) · Antibiotics · doi:10.3390/antibiotics9060312 · Cited by 474
Spampinato, C., & Leonardi, D. (2013) · BioMed Research International · doi:10.1155/2013/204237 · Cited by 411
Biofilm of Candida albicans : formation, regulation and resistance
Pereira, R., Santos Fontenelle, R. O., Brito, E. H. S., & Morais, S. M. (2021) · Journal of Applied Microbiology · doi:10.1111/jam.14949 · Cited by 368
Paulussen, C., Hallsworth, J. E., Álvarez‐Pérez, S., Nierman, W. C., Hamill, P. G., Blain, D., Rediers, H., & Lievens, B. (2017) · Microbial Biotechnology · doi:10.1111/1751-7915.12367 · Cited by 334
Metadata
- Authors
- Vandeputte, P., Ferrari, S., & Coste, A. T.
- Venue
- International Journal of Microbiology
- Publisher
- Wiley
- Published
- 2012
- Volume
- 2012
- Pages
- 1-26
- ISSN
- 1687-918X (ISSN-L)
- 1687-9198
- OpenAlex
- W2070654910
- Cited by
- 505
- References
- 271
- FWCI
- 11.01
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.